打开APP
首页 课程 直播 学堂
登录|注册

距开始播出还有

小时

肠道微生态与肝病专题论坛暨2021(第七届)肠道微生态与健康国际研讨会会前会

直播日期 2021/10/19 14:00

我要报名 进入直播观看

请先点击“我要报名”进行报名,直播开始前半小时,点击“进入直播观看”填写报名时的邮箱及手机号即可进入直播。

肠道微生态与肝病专题论坛暨2021(第七届)肠道微生态与健康国际研讨会会前会

人体肠道内寄生着大量的微生物,并对人体的代谢、免疫、发育等多种生理过程发挥重要的调节作用。在多种慢性肝病的发展过程中都伴随着肠道菌群的改变。一方面,肝脏疾病的发生可以影响肠道菌群的组成。比如,乙肝病毒的感染可以延缓肠道菌群的定植和成熟。另一方面,肠道菌群也能反过来影响肝脏疾病的发展。比如,当肠道菌群失衡时,肠道的通透性发生改变,肠道菌群能向肝脏内移位,抑制肝脏免疫,不利于乙肝病毒的清除。此外,肠道菌群在自身免疫性肝病、代谢性肝病、酒精性肝病的发生发展过程中都发挥这重要的作用。粪菌移植可以促进慢性乙型肝炎患者HBeAg抗原的下降,还可用于治疗肝性脑病。

因此,本论坛特邀华中科技大学附属协和医院王俊忠博士,围绕”肠道微生态与肝病“的最新前沿研究进行精彩分享!

Abstract


Approximately a trillion microbial cells colonize the mammalian intestine; these are collectively termed gut microbiota. Gut microbiota play a critical role in many physiological and pathological processes, influencing host immunity and metabolism. Gut dysbiosis is related to not only intestinal but also extra-intestinal diseases, including nervous system, respiratory, cardiovascular system, and liver diseases.

The liver is the largest internal organ and gland in the human body, which receives blood both from the portal vein and hepatic artery. Therefore, the liver is exposed to gut microbes as well as their metabolites and products. Previous studies showed that live commensal bacteria can be sampled by intestinal dendritic cells (DC) and transferred to the liver through the lymphatic route or portal vein. In healthy mice, the liver can act as a second firewall in which Kupffer cells can capture and clean commensal bacteria from the systemic vasculature. The healthy liver can maintain sterility by removing not only live commensal bacteria but also microbial metabolites and products.

Gut microbiota dysbiosis is related to chronic liver diseases, including alcoholic liver disease, non-alcoholic fatty liver disease, autoimmune liver disease, chronic hepatitis B and C, liver cirrhosis, and hepatocellular carcinoma (HCC). In mice, gut microbiota depletion was found to impair the HBV-specific T cell response and prolong HBV infection. In patients with hepatitis B-related cirrhosis, the gut microbiota community and metabolism mediated by the gut microbiota was significantly changed when compared with healthy controls. Reconstitution of the gut microbiota using fecal microbiota transplantation (FMT) facilitated hepatitis B virus e-antigen (HBeAg) clearance in patients with HBeAg-positive chronic hepatitis B after long-term antiviral therapy. FMT is also a potent therapy strategy for hepatic encephalopathy.

嘉宾简介

王俊忠博士(华中科技大学附属协和医院)

王俊忠博士毕业于华中科技大学,曾在德国杜伊斯堡-埃森大学和美国西北大学从事博士后和访问学者研究工作。对慢性病毒性肝炎、肝硬化、重型肝炎、自身免疫性肝病、代谢性肝病、血吸虫性肝病等的诊治具有丰富的临床经验,尤其是对病毒性肝炎的发病机制和免疫调节治疗有深入的研究,对肠道微生态在病毒性肝炎的发病机制中的研究有独特的见解,并开展了利用调节肠道微生态治疗肝性脑病的临床研究、利用肠道微生态及肠道功能的改变预测肝衰竭患者的临床转归及结局。获湖北省科技进步奖一等奖1项、教育部科技进步二等奖1项。主持国家自然科学基金1项,作为重要成员参与国家传染病防治重大专项课题、中国-德国国际科技合作与交流重大课题、国家自然科学基金等课题十余项。发表论文30余篇,参与编写全国大学本科生及研究生教材《传染病学》、《王宝恩肝脏病学》、《新发感染病学》等多部专著。

Biosketch

Dr. Junzhong Wang got his Medical Doctor degree from Huazhong University of Science and Technology, and worked as postdoctoral fellow in University of Duisburg-Essen in German and Northwestern University in US. Dr. Junzhong Wang is an expert in the field of hepatology, is proficient in diagnosis and treatment of many liver diseases, including viral hepatitis, liver cirrhosis, liver failure, autoimmune liver diseases, metabolic liver diseases, etc. Dr. Junzhong Wang also investigates the immune response and immunotherapy of the viral hepatitis, the cross-talk of the gut microbiota and immune cells in liver. His research indicated that HBV infection can delay the maturation of gut microbiota, and microbiota played a protective role for the antiviral immunity in liver. In addition, Dr. Junzhong Wang have carried out the clinical research to develop the therapy strategy for hepatic encephalopathy based on fecal microbiota transplantation.

其他讲堂

分享到微信朋友圈×